High expression of HMGN2 associated with poor prognosis in patients with glioma. (IMAGE)

Compuscript Ltd

High expression of HMGN2 associated with poor prognosis in patients with glioma.

Caption

(A) Differences in the expression level of the HMGN2 (mRNA sequencing) in different cancers versus adjacent normal tissues analyzed by GEPIA. The glioma samples, low-grade gliomas (LGG), and glioblastoma multiforme (GBM) are labeled in red/bold. (B) Analysis of HMGN2 expression in different grades of glioma via the TCGA, CGGA-693, and CGGA-325 databases. (C) Analysis of the prognostic significance of HMGN2 in glioma via the TCGA, CGGA-693, and CGGA-325 databases. (D) Immunohistochemical staining was performed to evaluate HMGN2 expression in glioma tissue samples (grade 2, n = 16; grade 3, n = 18; grade 4, n = 26). Scale bar for the image above, 100 μm; scale bar for the image below, 50 μm. (E) The KEGG and GO enrichment analyses were based on the differentially expressed genes associated with HMGN2. (F) GSEA analysis of differentially expressed genes enriched in KEGG_CELL_CYCLE genes set. (G) Relevance of HMGN2 across 14 functional states in different types of gliomas.

Credit

Genes & Diseases

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.